Worldwide, about 93 million are estimated to have diabetic retinopathy (DR).[1] Diabetic macular edema (DME) affects about 7% of diabetic patients and is the main cause for vision loss associated with DR.[2,3] In recent past, anti-vascular endothelial growth factor (VEGF) therapy has become first-line therapy for center-involved DME and are effective in improving and maintaining visual acuity, as shown in large-scale randomized controlled trials.[4–7]. This evidence concerns the gene VEGFA and diabetic macular edema.